Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
30

Summary

Conditions
  • Recurrent Follicular Lymphoma
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • Recurrent Chronic Lymphocytic Leukemia
  • Refractory Mantle Cell Lymphoma
  • Refractory Transformed Chronic Lymphocytic Leukemia
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Transformed B-Cell Non-Hodgkin Lymphoma
  • Refractory Lymphoplasmacytic Lymphoma
  • Recurrent Lymphoplasmacytic Lymphoma
  • Refractory Small Lymphocytic Lymphoma
  • Refractory Chronic Lymphocytic Leukemia
  • Refractory Follicular Lymphoma
  • Refractory Transformed Non-Hodgkin Lymphoma
  • Recurrent Mantle Cell Lymphoma
  • Recurrent Marginal Zone Lymphoma
  • Recurrent Small Lymphocytic Lymphoma
  • Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
  • Recurrent Transformed Chronic Lymphocytic Leukemia
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • Refractory Diffuse Large B Cell Lymphoma
  • Refractory Marginal Zone Lymphoma
Type
Interventional
Phase
Phase 1Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

OUTLINE: This is a phase I/II dose-escalation study of CD20-specific CAR T cell therapy. Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide intravenously (IV). Patients may also receive fludarabine IV. After 36-96 hour...

OUTLINE: This is a phase I/II dose-escalation study of CD20-specific CAR T cell therapy. Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide intravenously (IV). Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes. Patients will be actively participating in the study for approximately 15 months. The total time includes the time for the T cells to be made, the T cell infusion, and for approximately 12 months after the T cell infusion is given. After completion of study treatment, patients are followed up for a minimum of 15 years.

Tracking Information

NCT #
NCT03277729
Collaborators
  • National Cancer Institute (NCI)
  • Mustang Bio
Investigators
Principal Investigator: Mazyar Shadman Fred Hutch/University of Washington Cancer Consortium